The Inflation Reduction Act of 2022 fundamentally changed the economics of pharmaceutical manufacturing. When Medicare begins direct price negotiation on the first 10 high-spend drugs in 2026, it triggers a cascading cost pressure that runs directly to the active pharmaceutical ingredient (API) supply chain. Manufacturers face a paradox: IRA provisions compress margins by 40 to 70% on blockbuster and high-volume drugs, structurally rewarding the lowest-cost API sources. Yet at the same time, tariffs, Section 232 national-security investigations, and the new Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) executive order are pushing in the opposite direction — toward domestic production and supply chain diversification.
The data exposes the scale of the challenge. Less than 5% of large-scale API manufacturing sites worldwide are located in the United States. Only 12% of total API volume consumed by US prescription drug makers is produced domestically. The remaining 88% comes from India, the European Union, China, and other regions. India alone accounts for over half of API volume for US generic drugs. But India itself imports roughly 70 to 80% of its API key starting materials from China. The true concentration risk is deeper than headline numbers suggest.
The IRA Cost Paradox: Cheaper Drugs, Expensive Ingredients
IRA's Medicare Drug Price Negotiation Program authorizes the Centers for Medicare & Medicaid Services to directly negotiate prices on high-spend drugs. Starting with 10 drugs in 2026 and ramping to 20 per year by 2029, the program covers drugs that lack competition and represent significant Medicare expenditure. Manufacturers that refuse to negotiate face excise taxes of 65 to 95% of Medicare utilization, or must withdraw from Medicare and Medicaid entirely. Inflation rebate provisions further penalize price increases above the rate of inflation for Part B and Part D drugs.
Industry analyses project that IRA negotiation, combined with parallel US Most Favored Nation pricing initiatives, EU Health Technology Assessment reforms, and Asian volume-based procurement, will compress margins on affected products by 40 to 70%. For procurement teams, this creates intense pressure to reduce cost of goods sold. Since API cost represents 30 to 60% of finished drug manufacturing cost for most small-molecule products, the sourcing desk is where margin preservation must happen.
The structural problem is that the lowest-cost API supply is concentrated in exactly the regions that US policy now treats as supply-chain risks. Chinese APIs remain 30 to 40% cheaper than domestic equivalents. Despite tariffs, rising trade barriers, and repeated political commitments to reshoring, China's share of APIs supplied to US markets actually grew from 13% in 2019 to 20% in 2025. Cost pressure from IRA directly reinforces this dependence.
The Real Concentration: Tracing Dependence to Chinese Key Starting Materials
FDA registration data tells only part of the story. The US accounts for 22% of FDA-registered API manufacturing sites. India holds 21%. China holds 20% with 467 registered facilities as of February 2025, up from 230 facilities and a 13% market share in 2019. The European Union accounts for 19%. Facility counts understate actual dependency because Asian plants operate at larger scale. By production volume, China and India together supply roughly 80% of APIs used in US drugs.
The deeper vulnerability lies further up the supply chain. India is the world's third-largest pharmaceutical producer by volume and supplies about half of all finished generic drugs consumed in the United States. But India's pharmaceutical manufacturing capability rests on a fragile foundation: Chinese key starting materials (KSMs) and intermediates. Multiple industry sources consistently report that India imports 70 to 80% of its API and KSM requirements from China. For 45 specific essential APIs, India has historically been 100% dependent on Chinese inputs. Even when API manufacture occurs in India, the KSMs are primarily sourced from China.
Testimony submitted to the US-China Economic and Security Review Commission in June 2025 provided a stark adjustment: when India's secondary dependence on Chinese KSMs is factored in, approximately 46% of all US generic daily doses have source materials that originate in China. That is nearly half of every generic prescription filled in America, routed through a single country for its chemical precursors.
USP data further confirms the vulnerability. Over 80% of APIs for essential medicines — antibiotics, painkillers, antihypertensives, antidepressants — have no domestic manufacturing source at all. Of the largest API manufacturers serving the US market (those with more than 30 active US-approved API products), India accounts for 65%. A supply disruption at a handful of Indian facilities, themselves dependent on Chinese upstream inputs, would cascade across hundreds of drug products.
"The net effect is a pull in two directions: cost push toward offshore APIs vs. policy and national-security push toward reshoring and regional diversification. Resolving that tension is the central procurement challenge of the IRA era."
— Analysis of IRA impact on pharmaceutical supply chains, 2026FDA Quality Concerns: The Regulatory Risk in Offshore API Supply
IRA-driven cost pressure does not exist in isolation from quality risk. The FDA's enforcement record against API manufacturers in China and India is extensive and persistent. Of 75 FDA warning letters issued between early 2018 and early 2022, 37 — nearly half — targeted manufacturers in India or China. During the same period, 64% of European Medicines Agency compliance notices also went to facilities in those two countries.
Specific cases illustrate the pattern. In 2025, the FDA issued warning letters to Chinese API producers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical for significant CGMP deviations including data integrity failures and inadequate impurity control. Both were placed on Import Alert 66-40, blocking US imports. An Indian API manufacturer, Global Calcium, received a warning letter for quality control failures, data integrity manipulation, and inadequate facility maintenance. The FDA deemed its APIs adulterated under the Federal Food, Drug, and Cosmetic Act.
Another Indian manufacturer was cited for reusing inadequately cleaned equipment between different API production runs. Instead of addressing the underlying contamination, the company repeated tests until they appeared to pass. The FDA's data integrity findings go beyond isolated cases: falsified manufacturing records, manipulated test results, and inadequate quality unit oversight appear repeatedly in warning letters to overseas API facilities.
The consequences are not theoretical. When an overseas API producer receives an import alert, the US drug supply can lose a critical ingredient source overnight. The FDA has repeatedly emphasized that over 90% of APIs used in US drugs are manufactured abroad, and that warning letters to API firms in China and India reflect persistent concerns about data integrity, inadequate quality systems, and contamination risk. A 2025 advocacy analysis found evidence that Indian generics had a 54% higher risk of serious side effects than US-made equivalents, and that 22% of APIs in procurement data sets have unknown country of origin.
Policy Responses: SAPIR, Tariffs, and the Reshoring Push
The US policy response to API dependence has accelerated sharply since 2024. In April 2025, the Department of Commerce launched a Section 232 national security investigation into pharmaceutical imports, covering finished drugs, APIs, and key starting materials. The investigation led to a presidential proclamation imposing tariffs on certain patented pharmaceuticals and APIs, with rates varying by country. The stated objective is to reduce a pharmaceutical trade deficit that reached approximately $139 billion in 2024.
In August 2025, President Trump signed the Executive Order on Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The order tasks the Assistant Secretary for Preparedness and Response with identifying approximately 26 critical drugs and building stockpiles of their APIs. It explicitly aims to reduce foreign dependence and support domestic API production capacity through expanded federal contracting and incentives for facility expansion.
The executive order acknowledged what industry already knows: domestic API capacity may currently be insufficient to meet stockpile targets. The path forward implies capital subsidies, long-term federal contracts, and regulatory prioritization for new US API plants. The API Innovation Center (APIIC) in St. Louis is already working with industry partners including MilliporeSigma and Sentio BioSciences to develop domestically produced APIs for essential medicines.
Yet the policy signal is mixed. Tariffs on imported APIs raise costs for generic manufacturers already operating on thin margins. Without accompanying tax credits or production subsidies, tariffs can encourage manufacturers to seek even lower-cost offshore sources, potentially exacerbating quality risks. Critics argue that targeted manufacturing tax credits would be a more effective mechanism than tariffs alone for building sustainable domestic API capacity.
"The most resilient supply chains are those designed with optionality: diversified sourcing networks, qualified alternatives, and domestic manufacturing capabilities positioned to absorb disruption when it occurs."
— LGM Pharma, API Supply Chain Risk Analysis, 2026What Procurement Teams Must Do Now
IRA's margin compression and the regulatory push for supply chain security create contradictory pressures. Procurement teams cannot simply chase the lowest-cost API source when that source sits in a geopolitically exposed single point of failure. But they also cannot reshore everything overnight when domestic capacity barely exists and costs are 30 to 40% higher. The emerging industry consensus converges on a set of practical strategies.
Five Procurement Priorities for API Supply Chain Resilience Under IRA
- Dual source with geographic diversity. Qualify at least one API supplier outside the dominant production region. A US or allied-country anchor combined with an Indian or EU source provides redundancy against import alerts, tariffs, and geopolitical disruption.
- Treat supplier qualification as a multi-year project. Under FDA SUPAC and BACPAC guidance, changing an API source is classified as a major change requiring a Prior Approval Supplement. A BIO survey found 80% of biotech firms need at least 12 months to qualify alternative suppliers. Start now.
- Map upstream KSM dependencies. Your Indian API supplier may be excellent on quality but dependent on Chinese key starting materials. Supply chain mapping to the KSM level exposes hidden single points of failure that direct API sourcing does not.
- Invest in supplier quality intelligence. Frequent FDA warning letters for data integrity and quality unit failures at overseas sites mean that third-party audits, ongoing quality metrics, and contractual transparency obligations are not optional. A single import alert can shut off a critical API overnight.
- Build strategic inventory buffers for essential generics. SAPIR will cover 26 critical drugs at the federal level. Firms should identify their own critical molecules — the ones with no alternative source and thin margins that IRA negotiation will squeeze hardest — and hold differentiated safety stock.
The Reshoring Reality: Progress and Limits
Reshoring of API production is happening, but the pace is slow. AbbVie, Eli Lilly, and Johnson & Johnson have announced onshoring initiatives for select molecules. The IRA's domestic manufacturing tax credits, while primarily designed for clean energy and advanced manufacturing, provide some incentive structure for pharmaceutical companies to align new US investments with broader localization strategies.
But the numbers ground expectations. Less than 5% of large-scale API manufacturing sites are in the United States. Only 12% of API volume for US prescription drugs is domestically produced. Building a single new API facility takes three to five years and requires FDA inspection and approval before commercial production. The capital cost for a greenfield API plant starts at $100 million and can exceed $500 million for complex molecules. Even with federal contracts and state-level subsidies, the gap between ambition and capacity is measured in years, not quarters.
China's continued dominance is not accidental. Chinese API producers benefit from implicit government subsidies including lower power costs, currency advantages, and fewer regulatory burdens. These structural cost advantages persist even as tariffs and trade barriers increase. The result is that despite growing political will to reshore, China's API share for US markets has continued to grow.
Conclusion: The IRA Reshaping of API Procurement Is Here
IRA's Medicare drug price negotiation does not directly mandate changes to API sourcing. But its margin compression creates economic conditions that force procurement decisions. Manufacturers that do not address API supply chain concentration risk under IRA cost pressure are exposed on two fronts: they pay higher costs from a fragile supply base, or they accept concentration risk for marginal cost savings that erode as tariffs and regulatory costs rise.
The emerging playbook is clear. Dual source with geographic diversity. Map supply chains to the KSM level. Invest in supplier quality verification. Hold strategic inventory for critical molecules. Start the multi-year process of qualifying alternative suppliers now, before a warning letter, tariff escalation, or geopolitical event makes the decision for you.
Reshoring is a structural shift measured in years, not months. But the IRA has made it unavoidable. Procurement teams that act now — building optionality into their API networks, investing in domestic and allied-country anchors, and treating supplier qualification as a strategic project rather than a tactical purchase — will be the ones with drugs on the shelf when the next disruption hits.
Frequently Asked Questions
What share of US drug APIs come from China and India?
By production volume, approximately 80% of APIs used in US drugs come from facilities in China and India. Only 22% of FDA-registered API manufacturing sites are in the United States, and just 12% of total API volume for US prescription drugs is produced domestically.
How does the Inflation Reduction Act affect API sourcing?
IRA's Medicare drug price negotiation program compresses manufacturer margins by an estimated 40 to 70% on affected drugs. This creates intense pressure to reduce API costs, which structurally favors low-cost production regions like China and India. At the same time, IRA-related domestic manufacturing tax credits and parallel supply chain security policies push toward reshoring. The net effect is a tension that procurement teams must actively manage through dual sourcing and strategic supplier qualification.
What is the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR)?
SAPIR is a federal program established by Executive Order in August 2025 that directs the build-out of stockpiles of APIs for approximately 26 critical drugs. It aims to reduce dependence on foreign suppliers and support domestic API production capacity through federal contracting and facility expansion incentives.
What are the FDA quality risks with foreign API suppliers?
FDA warning letters to API manufacturers in China and India consistently cite data integrity failures, inadequate quality unit oversight, and gaps in impurity testing. Nearly half of FDA warning letters from 2018 to 2022 targeted facilities in these two countries. Violations can result in Import Alert 66-40, which blocks all shipments from the facility to the US market.
How long does it take to qualify an alternative API supplier?
A BIO survey from February 2025 found that 80% of biotech firms need at least 12 months to qualify alternative suppliers, and 44% would require more than two years. API site changes are classified as major changes under FDA SUPAC and BACPAC guidance, requiring a Prior Approval Supplement with demonstration of no adverse impact on drug quality or performance.